Atrial Fibrillation: A Case Study

This case study discusses the management of a 68 year old male who presented with chest palpitations secondary to rapid atrial fibrillation. Atrial fibrillation is a common cardiac arrhythmia with serious complications if not treated correctly. This essay will discuss the initial clinical presentation of the patient and examine the management and outcome of the interventions applied. The significance of atrial fibrillation including its pathophysiology and aetiology will also be discussed.

Coumadin (non specific name: warfarin) is an anticoagulant, or blood diminishing drug, that is endorsed to numerous patients who are at danger for creating blood clusters that could bring about heart assaults or strokes. Warfarin is near the most astounding purpose recently and simultaneous investigations of medications that provoke ER visits and occurring an expansion in healing center based offices with the affirmation of patients. Anticoagulation treatment stances perils to patients and over and over prompts unfavorable solution events in light of complex dosing, fundamental ensuing watching, and clashing patient consistence. As a result, various patients who meet current evidence based principles for warfarin treatment are not being managed

There are many people that suffer from venous thromboembolism. Venous thromboembolism includes both deep vein thrombosis and pulmonary embolism. This is the third most common cause of vascular death after a myocardial infarction, also known as a heart attack, and stroke. This article examines the possibility of either full or low intensity anticoagulation therapy versus aspirin. This was a randomized study that consisted of 3,396 individuals who have venous thromboembolism. These individuals either received rivaroxaban, which is an anticoagulant, or 100 mg of aspirin once a day. The individuals in this study completed 6-12 months of anticoagulation therapy and were eligible for inclusion in the study if they were 18 years of age or older. The

Other hemodynamic effects have also been reported with usage of ivabradine. In a study by Kurtoglu et al, ivabradine was seen to improve heart rate variability in non-ischemic patients with heart failure. (26). De Luca et al showed that addition of ivabradine to optimal medical therapy in patients with stable heart failure with preserved ejection fraction with New York Heart Association (NYHA) class II, left ventricular ejection fraction (LVEF) > 50% and heart rate > 70 bpm, significantly improved physical performance by increasing exercise capacity (27). Another study in patients with stable ischemic heart failure, NYHA functional class II and LVEF ≤ 40%, confirmed these findings and additionally showed an improved gas exchange (with improvement

I would like to express many thanks for my advisor Daryl Sieg for all of the support. I would also like to thank Dr. Klug for her guidance in the statistical aspect of this paper. Thank you to Allison Frank at the coagulation clinic in Fargo for taking the time to discuss my paper with me. Her view on these medications was very beneficial.

Henry Rollins once said; “Loneliness adds beauty to life. It puts a special burn on sunsets and makes night air smell better.” Although, loneliness is a part of life, nobody wants to feel alone or be in isolation. My mother passed away when I was 9. At that point in time she was the only person I looked up to, as a result the situation left me feeling alone. While other girls were learning how to wear makeup and how to cook from their mothers, I began teaching myself how to do these simple things. This experience has made me realize how important it is to appreciate what you have before it is too late. I am also more independent as a result.

Today millions of Americans live or have lived with Atrial fibrillation. The main concern with this health issue is that many people who lived with it sometimes are not aware of it. Atrial fibrillation is defined by Mayo Clinic (2012) as “an irregular and often rapid heart rate that commonly causes poor blood flow to the body”. It occurs when the four chambers of the heart have a disrupted rhythm. The abnormal functionality of health may lead to a stroke because of the possible blood clot that will be formed. The Atrial fibrillation or Afib put the body in a situation without oxygen and nutrients because the body is not well supplied by a heart that is became weak. In general, only few people will feel change in their heartbeat. They may verbalize

For many year’s patients with atrial fibrillation have been treated with anticoagulants such as Warfarin to prevent strokes and embolisms. Unfortunately, Warfarin must be closely monitored and that is an irritant for some patients. In October 2010, the FDA approved a new generational anticoagulant drug called Dabigatran (Pradaxa). This alternate medication gives patients the benefit of no dietary restrictions since dabigatran is not affected by certain foods. Another benefit of taking dabigatran is a monthly blood test is not required to measure its effectiveness, so for this particular reason many patients switch from taking other anticoagulants to dabigatran (Talati & White, 2011). Since this medication does not require close monitoring, some wonder if is it truly a better option or can more harm than good come from taking it. While the benefits of using dabigatran have shown significant improvement over warfarin, there are still risks associated with using dabigatran.

The heart is a complex yet delicate organ that operates the body on a regular basis. Without the heart the circulation system within the body would cease to exist; therefore, we would cease to exist. As with everything that is complex and works around the clock there are certain issues that can arise for example, atrial fibrillation. Atrial fibrillation is the result of an irregular or fast heartbeat this will often cause an inadequate circulation throughout the rest of the body. The atrium of the heart will not sync up to the ventricles causing an irregular or fast heartbeat.

There no direct cause as why to atrial fibrillation occur but, there is many other disease and disorders that Atrial Fibrillation is associated with. For example Atrial Fibrillation is closely associated with heart attack due to the fact that a during a heart attack the coronary artery is unable to supply oxygen to the heart which then causes the muscles in the heart to starve for oxygen. This can then lead to the death of some muscle tissue in the heart which then can lead to AFib. Hypertension also play a role in AFib, Hypertension (high blood pressure) is a constant high pressure of blood against the walls of the artery (arteries are the blood vessel that carry blood from the heart to our body parts) (A blood vessel is a tube which carries

Atrial fibrillation is a type of heart rhythm disorder called an ‘arrhythmia’. Atrial fibrillation is a condition that occurs when there is a fault in the electric activity in the heart muscle, causing the heart to beat irregularly and in an uncoordinated way.

Atrial fibrillation is one type of arrhymia, often rapid heart rate. Atrial fibrillation mean the atrial contract to quicky, disturbance between the atrial and the ventrical. AF usually isn’t life- threatening, however this is dangerous because the patient may not have symptoms, but it can increase risk of heart failure and stroke because the blood flow isn’t fluent.

You have made a great observation that, in order for Ana to receive quality health care at this facility, she is in need of a nutritional assessment in how to incorporate the restriction that she is now faced with, in regards to her recent diagnosis of Atrial fibrillation. I would agree, Ana and her brother will need assistance in getting Medicaid approved, as well as, locating any additional programs that she may now qualify for. Thank for sharing.

Atrial fibrillation is a common problem, with over 2 million people affected in the United States. Atrial fibrillation causes substantial morbidity and mortality, with an increased risk of ischemic stroke. Thus, it is important to recognize the risk factors associated with the disease to prevent it from occurring. In this review, being overweight and obese is positively correlated with increased risk of developing atrial fibrillation in both men and women. This review suggests that the excess risk of atrial fibrillation associated with obesity may be caused by the left atrial remodeling and enlargement caused by the excess adipose tissue, hemodynamic overload, and adipokines inflammatory response. This data raises the possibility that interventions to promote normal weight may reduce the burden of atrial fibrillation in the current and future population. A few of the recognized risk factors for atrial fibrillation are male sex, increasing age, hypertension, diabetes, ischemic heart disease, heart failure, and heart valve disease (13). It has been known for more than 75 years that a critical mass of atrial tissue is necessary for atrial fibrillation to occur and left atrial enlargement is also an important precursor of atrial fibrillation (3). Several studies have shown that BMI is one of the most powerful determinants of the left atrial size needed for developing atrial fibrillation (3), so getting BMI lowered by exercise and a good diet should be of high priority

Clinical freedom is the right of medical practitioners to decide and do whatever in their opinion was best for their patients. It had been common practice that medical practitioners subject patients to treatment procedures without any evidence of their efficacy, which not only will increase expenditures, but also may put patients to potential harm. Hampton considered clinical freedom as a myth and ‘a cloak of ignorance’, and believed that medical practitioners should base their clinical practice on evidence from randomized controlled trials to guide medical decision making and set aside dogma and biases (1). Using an example from the issue of active management of myocardial infarction, the author highlighted the importance of managing resources effectively on clinical and economic considerations, and suggested that interventions should not only be assessed for their efficacy in increasing likelihood of their desired effect, but also assessed with comparative trials against other alternative treatments. (1). In his conclusion, author felt that the end of clinical freedom is not to be regretted, for its end would allow treatment to be applied only after a properly conducted clinical trial and approved on a large scale after considering available resources and the efficacy of treatment.